Ensoma
Developing curative medicines through precision in vivo cellular engineering.
Developing curative medicines through precision in vivo cellular engineering.
Sector
Life SciencesCategory
TherapeuticsLocation
Boston, MAInitial Investment
2021
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy).